talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
Published 8 months ago • 68 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
11:19
drs. fizazi, wallis on updated data from talapro-2
-
3:06
titan trial
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
6:35
talazoparib plus enzalutamide: talapro-2 results and subset analyses
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
2:53
advin turp set / bipolar resectoscope set - active - single stem - karl storz compatible
-
31:13
titan trial | investigating the addition of apalutamide to androgen deprivation therapy
-
7:48
new treatment option for metastatic hormone-sensitive prostate cancer
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
4:05
presto study
-
7:01
transplant medicines - tacrolimus (prograf®)
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
6:00
arches trial
-
5:21
talapro-2 phase iii study design
-
4:49
dasl-hicap (anzup1801) trial
-
4:26
prolaris® test report explanation video
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
1:14
tarlatamab mechanism of action
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal